
Kymera Therapeutics KYMR
$ 74.13
-0.64%
Annual report 2025
added 02-26-2026
Kymera Therapeutics Cash Conversion Cycle 2011-2026 | KYMR
Annual Cash Conversion Cycle Kymera Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.6 | -50.6 | -26.5 | -32.5 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -26.5 | -50.6 | -39.1 |
Quarterly Cash Conversion Cycle Kymera Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -186 | -63.8 | -33.5 | - | -159 | -23.7 | -61.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -23.7 | -186 | -87.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-3.12 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Compugen Ltd.
CGEN
|
-82.7 | $ 2.1 | -5.41 % | $ 196 M | ||
|
Coherus BioSciences
CHRS
|
149 | $ 1.45 | -7.94 % | $ 170 M | ||
|
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 51.84 | -8.97 % | $ 4.66 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Celyad Oncology SA
CYAD
|
-55.7 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
-3.74 K | $ 28.62 | -4.38 % | $ 1.9 B | ||
|
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-981 | $ 0.71 | -10.18 % | $ 32.4 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
115 | $ 29.13 | 0.8 % | $ 784 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | ||
|
Anika Therapeutics
ANIK
|
192 | $ 14.48 | -2.1 % | $ 208 M | ||
|
Advaxis
ADXS
|
-82.3 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M |